Portal de investigação
Predictors of lung entrapment in malignant pleural effusion
Dados básicos
- Código:
- Estudo Clínico Académico
- Protocolo:
- Estudo Clínico Académico
- EUDRACT:
- NCT:
- Centro:
- Dotação:
- Ano de início:
- 2022
- Ano de conclusão:
Objectivos do projeto
Estudos Observacionais (STROBE statement); Natureza do Promotor: Academia – Tipo não comercial – Iniciativa do Investigador; Tipo de Centro: Unicêntrico – Cuidados Secundários
Documentos
- Não há documentos
Participantes
Unidades de investigação
Stakeholders - Promotores
Outputs do ensaio clínico
12-Gene Expression Signature: A Potential Key for Predicting Prognosis and Benefit to ACT for Resectable NSCLC Patients
Siqueira, A; (...); Leal, LF
Meeting Abstract. 2023
Clinical outcomes of patients with acute exacerbations in interstitial lung diseases
Meeting Abstract. 10.1183/13993003.congress-2022.4266. 2022
Coexistence of pleuroparenchymal fibroelastosis and hypersensitivity pneumonitis - analysis of prognostic impact
Meeting Abstract. 10.1183/13993003.congress-2022.4094. 2022
COVID-19 in interstitial lung diseases: are fibrotic ILDs associated with worse outcomes?
Meeting Abstract. 10.1183/13993003.congress-2022.3230. 2022
Deciphering the genetic tapestry: Insights into sarcoidosis across diverse populations with the MESARGEN Consortium
Meeting Abstract. 10.1183/13993003.congress-2024.OA952. 2024
Deregulated immune cell recruitment orchestrated by c-MET impairs pulmonary inflammation and fibrosis
Article. 10.1186/s12931-024-02884-1. 2024
Distinct TNF-alpha and HLA polymorphisms associate with fibrotic and non-fibrotic subtypes of hypersensitivity pneumonitis
Freitas, C; (...); Morais, A
Article. 10.1016/j.pulmoe.2021.08.013. 2023
Efficacy and Safety of Indwelling Catheter for Malignant Pleural Effusions Related to Timing of Cancer Therapy: A Systematic Review
Porcel, JM; (...); Botana-Rial, M
Review. 10.1016/j.arbres.2023.06.007. 2023
Efficacy of mycophenolate mofetil in fibrotic hypersensitivity pneumonitis treatment
Meeting Abstract. 10.1183/13993003.congress-2023.PA410. 2023
Evolution of fibrotic interstitial lung diseases (ILD) after COVID-19
Meeting Abstract. 10.1183/13993003.congress-2022.4172. 2022
Fungal stimulation induces a specific Th1-like immune response in hypersensitivity pneumonitis patients
Meeting Abstract. 10.1183/13993003.congress-2024.PA2454. 2024
Home environmental fungal exposure in patients with Hypersensitivity Pneumonitis
Meeting Abstract. 10.1183/13993003.congress-2024.PA1581. 2024
Home environmental fungal exposure in patients with Hypersensitivity Pneumonitis - pilot analysis
Meeting Abstract. 10.1183/13993003.congress-2022.4281. 2022
Hypersensitivity Pneumonitis with and without Autoimmune Features: a comparative analysis at diagnosis
Meeting Abstract. 10.1183/13993003.congress-2024.PA1573. 2024
Immunotherapy in metastatic non-small cell lung cancer: EPSILoN as a prognostic score
Valente, MCA; (...); Hespanhol, V
Meeting Abstract. 10.1183/13993003.congress-2022.3572. 2022
Metabolic regulation of granulomatous inflammation by tryptophan catabolism
Meeting Abstract. 10.1183/13993003.congress-2024.PA2478. 2024
Monocyte/macrophage axis as potential drivers of Progressive Fibrosing Hypersensitivity Pneumonitis
Meeting Abstract. 10.1183/13993003.congress-2023.PA1164. 2023
OBSTRUCTIVE SLEEP APNEA IN NON-IPF FIBROTIC ILD PATIENTS: WHO, HOW AND WHAT SHOULD WE OFFER?
Meeting Abstract. 2024
Pentraxin 3 Inhibits Complement-driven Macrophage Activation to Restrain Granuloma Formation in Sarcoidosis
Gonçales, RA; (...); Carvalho, A
Article. 10.1164/rccm.202112-2771OC. 2022
Polymorphisms and haplotypes of TOLLIP and MUC5B are associated with susceptibility and survival in patients with fibrotic hypersensitivity pneumonitis
Article. 10.1016/j.pulmoe.2024.01.002. 2024
Predictors of immune-related adverse events and outcomes in patients with NSCLC treated with immune-checkpoint inhibitors
Serino M.; (...); Hespanhol V.
Article. 10.1016/j.pulmoe.2022.03.003. 2024
Predictors of immune-related adverse events and outcomes in patients with NSCLC treated with immune-checkpoint inhibitors.
Article. 2024
Predictors of lung entrapment in malignant pleural effusion
Article. 10.1016/j.pulmoe.2022.08.001. 2024
Reproducibility of a 12-gene set for predicting outcome and benefit from ACT in earlystage NSCLC patients
Meeting Abstract. 10.1183/13993003.congress-2023.OA1451. 2023
Risk Factors for Acute Exacerbations of Fibrotic Hypersensitivity Pneumonitis-Is Exposure a Trigger That We're Missing?
Coelho, DB; (...); Melo, N
Letter. 10.1016/j.arbres.2022.07.004. 2023
Serum metalloproteinase 7 as a biomarker of progressive pulmonary fibrosis
Araújo, M; (...); Morais, A
Meeting Abstract. 10.1183/13993003.congress-2023.PA1155. 2023
Serum metalloproteinase-7 as a biomarker of progressive pulmonary fibrosis
Article. 10.1183/23120541.00553-2024. 2024
Spread through air spaces prognostic value in adenocarcinoma
Meeting Abstract. 10.1183/13993003.congress-2023.PA2214. 2023
The impact of nintedanib and pirfenidone on lung function and survival in patients with idiopathic pulmonary fibrosis in real-life setting
Santos, G; (...); Morais, A
Article. 10.1016/j.pupt.2023.102261. 2023
Transbronchial lung cryobiopsy for the diagnosis of Fibrotic Hypersensitivity Pneumonitis
Meeting Abstract. 10.1183/13993003.congress-2023.PA2919. 2023
Unveiling common molecular pathways linked to ILDs with progressive fibrosing phenotype: the role of MUC5B promoter variants
Meeting Abstract. 10.1183/13993003.congress-2023.OA854. 2023
Validation of a 5-gene signature for predicting outcomes in early-stage NSCLC patients
Meeting Abstract. 10.1183/13993003.congress-2023.OA1449. 2023
